These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


129 related items for PubMed ID: 37776957

  • 1. PAX1 expression in thymic epithelial neoplasms and morphologic mimics.
    Parrack PH, Hornick JL, Sholl LM.
    Hum Pathol; 2023 Dec; 142():7-14. PubMed ID: 37776957
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms.
    Nonaka D, Henley JD, Chiriboga L, Yee H.
    Am J Surg Pathol; 2007 Jul; 31(7):1038-44. PubMed ID: 17592270
    [Abstract] [Full Text] [Related]

  • 3. Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1.
    Weissferdt A, Tang X, Wistuba II, Moran CA.
    Mod Pathol; 2013 Dec; 26(12):1554-60. PubMed ID: 23787439
    [Abstract] [Full Text] [Related]

  • 4. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis.
    Weissferdt A, Moran CA.
    Am J Surg Pathol; 2011 Sep; 35(9):1305-10. PubMed ID: 21836478
    [Abstract] [Full Text] [Related]

  • 5. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors.
    Chan JK, Tsang WY, Seneviratne S, Pau MY.
    Am J Surg Pathol; 1995 Oct; 19(10):1115-23. PubMed ID: 7573670
    [Abstract] [Full Text] [Related]

  • 6. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
    Pan CC, Chen PC, Chou TY, Chiang H.
    Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
    [Abstract] [Full Text] [Related]

  • 7. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes.
    Thomas de Montpréville V, Quilhot P, Chalabreysse L, De Muret A, Hofman V, Lantuéjoul S, Parrens M, Payan MJ, Rouquette I, Secq V, Girard N, Besse B, Marx A, Molina TJ.
    Pathol Res Pract; 2015 Dec; 211(12):996-1002. PubMed ID: 26534878
    [Abstract] [Full Text] [Related]

  • 8. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
    Kojika M, Ishii G, Yoshida J, Nishimura M, Hishida T, Ota SJ, Murata Y, Nagai K, Ochiai A.
    Mod Pathol; 2009 Oct; 22(10):1341-50. PubMed ID: 19648882
    [Abstract] [Full Text] [Related]

  • 9. Combined Thymic Epithelial Neoplasms - a Review.
    Weissferdt A.
    Int J Surg Pathol; 2023 Sep; 31(6):917-926. PubMed ID: 36036356
    [Abstract] [Full Text] [Related]

  • 10. The clinicopathological significance of thymic epithelial markers expression in thymoma and thymic carcinoma.
    Li H, Ren B, Yu S, Gao H, Sun PL.
    BMC Cancer; 2023 Feb 16; 23(1):161. PubMed ID: 36797681
    [Abstract] [Full Text] [Related]

  • 11. PAX5 and CD70 are expressed in thymic carcinoma but not in atypical thymoma (WHO type B3 thymoma): an immunohistochemical analysis of 60 cases.
    Weissferdt A, Moran C.
    J Clin Pathol; 2024 Oct 20; 77(11):761-765. PubMed ID: 37696593
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemistry for YAP1 N-terminus and C-terminus highlights metaplastic thymoma and high-grade thymic epithelial tumors by different staining patterns.
    Yamada Y, Küffer S, Sauer C, Hoki M, Shibuya S, Tsujii H, Ono K, Moriyoshi K, Date H, Yoshizawa A, Szolkowska M, Haga H, Ströbel P, Marx A.
    Virchows Arch; 2024 Sep 20; 485(3):461-469. PubMed ID: 39096416
    [Abstract] [Full Text] [Related]

  • 13. CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma.
    Kanamori K, Suina K, Shukuya T, Takahashi F, Hayashi T, Hara K, Saito T, Mitsuishi Y, Shimamura SS, Winardi W, Tajima K, Ko R, Mimori T, Asao T, Itoh M, Kawaji H, Suehara Y, Takamochi K, Suzuki K, Takahashi K.
    Thorac Cancer; 2023 Apr 20; 14(12):1089-1097. PubMed ID: 36924358
    [Abstract] [Full Text] [Related]

  • 14. MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.
    Kaira K, Murakami H, Serizawa M, Koh Y, Abe M, Ohde Y, Takahashi T, Kondo H, Nakajima T, Yamamoto N.
    Virchows Arch; 2011 May 20; 458(5):615-20. PubMed ID: 21253760
    [Abstract] [Full Text] [Related]

  • 15. Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems.
    Walts AE, Hiroshima K, Marchevsky AM.
    Ann Diagn Pathol; 2015 Aug 20; 19(4):216-20. PubMed ID: 25979154
    [Abstract] [Full Text] [Related]

  • 16. Expression of proteasome subunit β5t in thymic epithelial tumors.
    Yamada Y, Tomaru U, Ishizu A, Kiuchi T, Marukawa K, Matsuno Y, Kasahara M.
    Am J Surg Pathol; 2011 Sep 20; 35(9):1296-304. PubMed ID: 21836487
    [Abstract] [Full Text] [Related]

  • 17. High levels of expression of Trop-2 in thymic epithelial tumors.
    Yeung V, Zaemes J, Yeh J, Giancarlo C, Ahn J, Reuss JE, Kallakury BV, Liu SV, Duttargi A, Khan G, Kim C.
    Lung Cancer; 2023 Oct 20; 184():107324. PubMed ID: 37573703
    [Abstract] [Full Text] [Related]

  • 18. A comprehensive analysis of PAX8 expression in human epithelial tumors.
    Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS.
    Am J Surg Pathol; 2011 Jun 20; 35(6):816-26. PubMed ID: 21552115
    [Abstract] [Full Text] [Related]

  • 19. Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
    Kuo TT, Chan JK.
    Am J Surg Pathol; 1998 Dec 20; 22(12):1474-81. PubMed ID: 9850173
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic roles of MUC1 and GLUT1 in differentiating thymic carcinoma from type B3 thymoma.
    Du MJ, Shen Q, Yin H, Rao Q, Zhou MX.
    Pathol Res Pract; 2016 Nov 20; 212(11):1048-1051. PubMed ID: 27688088
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.